CRISPR Therapeutics AG's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Quarterly earnings reports show whether a company is making progress and spending money wisely.
Stock plans let employees own company shares, aligning their interests with investor success.
Raising money helps companies fund operations and growth, but adds debt obligations investors should track.
Increased funding gives companies more cash but dilutes existing shareholders if notes convert to stock.
Quarterly earnings show revenue, spending, and progress toward company goals over three months.
Quarterly filings provide complete financial data showing assets, liabilities, and operational performance.
Quarterly filings show complete financial details investors need to evaluate company health.
Stocky reads CRISPR Therapeutics AG's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
CRISPR Therapeutics AG's most recent tracked filing was a 10-Q on 3 Aug 2026: Reported Q2 2026 financial results and business highlights.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.